EUVIMEDEUVIMED entdecken
Crossref

Identification and optimization of nitrophenolic analogues as dopamine metabolic enzyme inhibitors for the treatment of Parkinson’s disease

Manxing Zou, Yulu Wu, Yudan Lan, Huanfang Xie, Haopeng Sun, Wenyuan Liu, Feng Feng, Xueyang Jiang

Bioorganic Chemistry · 2024

DOI: 10.1016/j.bioorg.2024.107488 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Manxing Zou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China. Hauptthemen laut MEDLINE: Dopamine, Monoamine Oxidase, Monoamine Oxidase Inhibitors, Parkinson Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Progressive loss of dopaminergic neurons leads to the depletion of the striatal neurotransmitter dopamine, which is the main cause of Parkinson's disease (PD) motor symptoms. Simultaneous inhibition of the two key dopamine metabolic enzymes, catechol-O-methyltransferase (COMT) and monoamine oxidase B (MAO-B), could potentially be a breakthrough in achieving clinical efficacy. Representative compound C12 exhibits good COMT inhibitory activity (IC50 = 0.37 μM), metal chelation ability, and BBB permeability. Furthermore, results from in vivo biological activity evaluations indicate that C12 can improve dopamine levels and ameliorate MPTP-induced PD symptoms in mice. Preliminary in vivo and in vitro study results highlight the potential of compound C12 in PD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DopamineMonoamine OxidaseMonoamine Oxidase InhibitorsParkinson DiseaseAnimalsMiceStructure-Activity RelationshipMolecular StructureCatechol O-MethyltransferaseMice, Inbred C57BLMaleCatechol O-Methyltransferase InhibitorsHumansDose-Response Relationship, DrugAntiparkinson Agents

Stichwörter der Autor:innen

Catechol-O-methyltransferaseDopamine metabolizing enzymesMonoamine oxidaseParkinson’s disease

Substanzen

DopamineMonoamine OxidaseMonoamine Oxidase InhibitorsCatechol O-MethyltransferaseCatechol O-Methyltransferase InhibitorsAntiparkinson Agents

Autor:innen und Institutionen

  • Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China.
  • Department of Medicinal Chemistry, Anhui University of Chinese Medicine, Hefei 230012, China.
  • Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China.
  • Department of Pharmaceutical Analysis, Key Laboratory of Drug Quality Control and Pharmacovigilance, China Pharmaceutical University, Nanjing 211198, China.
  • Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China; Nanjing Medical University, Nanjing 211198, China.
  • Department of Medicinal Chemistry, Anhui University of Chinese Medicine, Hefei 230012, China. Electronic address: jiang0568@126.com.

Zitieren

APA

Zou, M., Wu, Y., Lan, Y., Xie, H., Sun, H., Liu, W., Feng, F., & Jiang, X. (2024). Identification and optimization of nitrophenolic analogues as dopamine metabolic enzyme inhibitors for the treatment of Parkinson’s disease. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2024.107488

Vancouver

Zou M, Wu Y, Lan Y, Xie H, Sun H, Liu W, et al. Identification and optimization of nitrophenolic analogues as dopamine metabolic enzyme inhibitors for the treatment of Parkinson’s disease. Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2024.107488

BibTeX
@article{Zou2024,
  author = {Zou, Manxing and Wu, Yulu and Lan, Yudan and Xie, Huanfang and Sun, Haopeng and Liu, Wenyuan and Feng, Feng and Jiang, Xueyang},
  title = {Identification and optimization of nitrophenolic analogues as dopamine metabolic enzyme inhibitors for the treatment of Parkinson’s disease},
  journal = {Bioorganic Chemistry},
  year = {2024},
  doi = {10.1016/j.bioorg.2024.107488}
}
Kostenlos starten →